1-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)

263  relevant articles (7 outcomes, 50 trials/studies) found for this Bio-Agent

PAF Acetylhydrolase; Lipoprotein-Associated Phospholipase A(2); Lipoprotein-Associated Phospholipase A2; Lp-PLA(2); Lp-PLA2; PAF 2-Acetylhydrolase; PAF 2-Acylhydrolase; PAF Acetylhydrolase II; Platelet-activating Factor Acetylhydrolase IB; 1 Alkyl 2 acetylglycerophosphocholine Esterase; 2-Acetylhydrolase, PAF; Acetylhydrolase II, PAF; Acetylhydrolase, PAF; Esterase, 1-Alkyl-2-acetylglycerophosphocholine; Factor Hydrolase, Platelet-Activating; Hydrolase, Platelet-Activating Factor; Lipoprotein Associated Phospholipase A2; Lp PLA2; PAF 2 Acetylhydrolase; PAF 2 Acylhydrolase; Phospholipase A2, Lipoprotein-Associated; Platelet Activating Factor Hydrolase; Platelet activating Factor Acetylhydrolase IB; Platelet-Activating Factor Hydrolase

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Tselepis, Alexandros D: 10 articles (10/2007 - 12/2002)
2.	McConnell, Joseph P: 7 articles (06/2008 - 05/2004)
3.	Koenig, Wolfgang: 5 articles (01/2008 - 09/2005)
4.	Nelson, Jeanenne J: 4 articles (09/2008 - 01/2005)
5.	Khuseyinova, Natalie: 4 articles (01/2008 - 09/2005)
6.	Lourida, Evangelia S: 4 articles (01/2007 - 11/2004)
7.	Elisaf, Moses: 4 articles (07/2005 - 01/2004)
8.	Folsom, Aaron R: 3 articles (07/2008 - 02/2004)
9.	Anderson, Jeffrey L: 3 articles (06/2008 - 11/2006)
10.	Lerman, Amir: 3 articles (06/2008 - 05/2007)

Related Diseases

1.	Atherosclerosis (Atheroma) 09/01/2007 - "In addition, the quantitative contribution of Lp-PLA2 to risk assessment was assessed in a substudy of the Atherosclerosis Risk in Communities (ARIC) study" 01/01/2007 - "Recent studies demonstrate that Lp-PLA(2) is also associated with endothelial dysfunction and early atherosclerosis" 11/01/2006 - "We investigated whether Lp-PLA2 activity and PLA2G7 A379V genotype were related to mediators of atherosclerosis in a diabetic study" 03/01/2006 - "Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: the Rotterdam Study." 10/01/2005 - "Genetic and animal model studies give varying indications as to the contribution of Lp-PLA(2) to atherogenesis and tend to support the view that higher Lp-PLA(2) levels are cardioprotective" Get all the results and reference details, order at left...
2.	Coronary Disease (Coronary Heart Disease) 03/04/2008 - "Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study." 08/01/2005 - "Although epidemiology studies consistently support a relationship between plasma Lp-PLA2 levels and susceptibility to coronary heart disease this is not the case for Lp-PLA2 polymorphisms" 09/01/2007 - "Whereas the first activity may be considered antiatherogenic, the prevailing consensus is that Lp-PLA2 is positively associated with coronary disease" 11/01/2006 - "Quartiles of UKPDS coronary heart disease (CHD) risk score were also positively associated with Lp-PLA2 activity (p=0.006, p=0.004 linear trend)" 07/01/2006 - "OBJECTIVE: We sought to evaluate whether lipoprotein-associated phospholipase A2 (Lp-PLA2), an emerging marker of cardiovascular risk, is associated with prognosis in patients with coronary heart disease (CHD)" Get all the results and reference details, order at left...
3.	Stroke (Strokes) 11/01/2007 - "After adjustment for baseline characteristics, patients in higher quartiles of Lp-PLA2 remained at significantly greater risk for the composite of cardiovascular death, MI, coronary revascularization, UA, or stroke (P<0.001 for trend, adj HR 1.41, 95% CI 1.17 to 1.70, for patients in 4th versus 1st quartile)" 06/16/2008 - "Over 25 prospective epidemiologic studies have demonstrated the association of elevated Lp-PLA(2) levels with future coronary events and stroke-11 of 12 prospective studies have shown a statistically significant association between elevated Lp-PLA(2) and primary coronary or cardiovascular events, 12 of 13 have shown a statistically significant association with recurrent coronary or cardiovascular events, and 6 studies have shown a positive association with stroke" 04/01/2008 - "Few studies have investigated the role of elevated lipoprotein-associated phospholipase A2 (Lp-PLA(2)) with stroke risk, and those that have are based on small numbers of strokes" 01/01/2006 - "At least two recent studies have shown that Lp-PLA2 is a risk predictor for stroke" 09/01/2008 - "In an age-, sex- and CV risk factors-adjusted Cox regression analysis, comparing top to bottom tertile of Lp-PLA(2) activity, the relative risk [RR; 95% confidence interval (CI)] for incident CHD and ischemic stroke events were 1.48; 0.92-2.37 and RR: 1.94; 1.15-3.26, respectively" Get all the results and reference details, order at left...
4.	Cardiovascular Diseases (Cardiovascular Disease) 01/01/2007 - "Among them, lipoprotein-associated phospholipase A(2) (Lp-PLA(2)), seems to be a promising candidate that might be added to the clinical armamentarium for improved prediction of cardiovascular disease in the future" 09/01/2007 - "INTRODUCTION: In some community-based studies, lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) has been shown to be independently predictive of future fatal and nonfatal cardiovascular disease (CVD) events" 02/01/2007 - "Synthesis of the available observational studies of Lp-PLA2 will yield information on a total of about 15 000 cardiovascular disease endpoints." 02/01/2007 - "Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases." 01/01/2006 - "Since several studies have demonstrated increased risk associated with the second and third tertiles vs. the first tertile for Lp-PLA2, the 50th percentile cut point (235 ng/mL) is recommended as a conservative cut point associated with increased risk for cardiovascular disease" Get all the results and reference details, order at left...
5.	Anaphylaxis (Anaphylactic Shock) 02/25/2000 - "The protective effect of PAF acetylhydrolase on mortality in this model was significant at 1.0 mg/kg. These results suggest that PAF is an important mediator in the lethality of systemic anaphylaxis, and that PAF acetylhydrolase may be beneficial for treatment of anaphylactic shock." 01/03/2008 - "Failure of PAF acetylhydrolase to inactivate PAF may contribute to the severity of anaphylaxis." 01/03/2008 - "PAF acetylhydrolase activity was significantly lower in patients with fatal anaphylactic reactions to peanuts than in patients in any of the control groups" 01/03/2008 - "CONCLUSIONS: Serum PAF levels were directly correlated and serum PAF acetylhydrolase activity was inversely correlated with the severity of anaphylaxis" 01/03/2008 - "Serum PAF acetylhydrolase activity was significantly lower in patients with fatal peanut anaphylaxis than in control patients (P values <0.001 for all comparisons)" Get all the results and reference details, order at left...
113 Diseases and 263 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Platelet Activating Factor
2.	LDL Cholesterol
3.	Pravastatin (Pravachol)
4.	Enzymes
5.	Lysophosphatidylcholines (Lysophosphatidylcholine)
6.	atorvastatin (Lipitor)
7.	Nonesterified Fatty Acids (NEFA)
8.	Aryldialkylphosphatase (Paraoxonase)
9.	Cytokines
10.	Simvastatin (Zocor)
108 Drugs and Important Bio-Agents and 173 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Intensive Care (Surgical Intensive Care)
2.	Blood Component Removal (Apheresis)
2 Therapies and Procedures and 2 more articles analyzed in the Research Interface, order at left...